Abstract |
Cyclophosphamide (CYC) has long been considered a gold standard in inducing renal remission and preventing renal flares for patients with systemic lupus erythematosus (SLE). However, the rational use of CYC has not reached a consensus, such as the timing and length of treatment, the route of administration, and the ideal dosage. The objective of this study was to assess the efficacy and safety of short-interval lower-dose (SILD) intravenous (IV) CYC in the treatment of SLE. A total of 225 patients with lupus nephritis were randomly assigned to a 1-year trial, either the SILD group (12 fortnightly pulses at a fixed dose of 400 mg followed by 6 monthly pulses) or high-dose (HD) group (6 monthly pulses followed by two quarterly pulses at a dose of 0.5~1.0 g/m(2)). At 6 months of treatment, 28 % (30/107) of patients in the SILD group reached a complete remission (CR), and 51.4 % (55/107) were in partial remission (PR), as compared with 32.7 % (35/107) and 45.8 % (49/107) in the HD group, respectively. Serum albumin, 24-h urinary protein, and the scores of disease activity were significantly improved in both groups at 6 months and maintained at the end of clinical trial. However, the SILD group showed much less menstrual disturbances (11.5 %), gastrointestinal adverse effects (5.3 %), and leukopenia (9.7 %) than the HD group (28.6, 26.8, and 19.8 %, respectively) at the end of clinical trial. The efficacy of the short-interval lower-dose (SILD) IV CYC regimen in the treatment of lupus nephritis is equivalent to that of the high-dose (HD) regimen, whereas the incidence of adverse events is much lower in the SILD group.
|
Authors | X W Zhang, Chun Li, X X Ma, J X Zhao, Yuan An, Shuang Liu, Yan Li, Z G Li |
Journal | Clinical rheumatology
(Clin Rheumatol)
Vol. 33
Issue 7
Pg. 939-45
(Jul 2014)
ISSN: 1434-9949 [Electronic] Germany |
PMID | 24744152
(Publication Type: Journal Article, Observational Study, Randomized Controlled Trial)
|
Chemical References |
- Immunosuppressive Agents
- Serum Albumin
- Cyclophosphamide
|
Topics |
- Adult
- Cyclophosphamide
(administration & dosage)
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Immunosuppressive Agents
(administration & dosage)
- Injections, Intravenous
- Lupus Erythematosus, Systemic
(complications, drug therapy)
- Lupus Nephritis
(drug therapy)
- Menstrual Cycle
(drug effects)
- Middle Aged
- Prospective Studies
- Proteinuria
(diagnosis)
- Remission Induction
- Serum Albumin
(analysis)
- Time Factors
- Treatment Outcome
|